The U.S. FDA has approved Bristol-Myers Squibb Company (NYSE:BMY)’s oral blood-cancer drug iberdomide, sold as Zenbexus, for patients with relapsed or refractory multiple myeloma. The treatment is given with Johnson & Johnson’s Darzalex and dexamethasone.
The approval gives BMY another product that could support growth in its oncology business. Iberdomide belongs to a newer class of drugs called CELMoDs. These drugs target the cereblon protein and are designed to help the body get rid of myeloma cells. The FDA’s decision was supported by late-stage data showing that the treatment improved minimal residual disease rates compared with standard therapy.
Zenbexus has a list price of $29,500 for a 28-day treatment cycle, and Bristol-Myers Squibb Company (NYSE:BMY) expects the drug to reach patients within the next few weeks. About 36,000 new multiple myeloma cases are expected in the U.S. this year, giving BMY a large market to target.
Growth Drivers
The approval gives Bristol-Myers Squibb Company (NYSE:BMY) another opportunity to strengthen its position in multiple myeloma. If Zenbexus gains broad adoption, the large patient pool and $29,500 list price could make it a meaningful source of revenue for the company.
The clinical results also give Zenbexus a good starting point. The late-stage study showed a significant improvement in minimal residual disease rates, suggesting that the drug could help patients whose cancer has returned or stopped responding to earlier treatment. Another study is looking at progression-free survival, which could add to the evidence around the drug’s benefits.
There is also potential upside from BMY’s wider CELMoD pipeline. The company is developing mezigdomide, another drug from the same class. If these treatments perform well, Bristol Myers could build a broader multiple myeloma franchise around the technology rather than relying on a single drug.
Key Risks
The biggest risk is that Zenbexus received accelerated approval, which means Bristol Myers still has to confirm its clinical benefit in ongoing trials. That makes the FDA decision encouraging, but not the end of the regulatory process. If the confirmatory trials fail to show the expected benefit, the drug could face further regulatory scrutiny.
Safety requirements could also weigh on sales. Zenbexus carries the FDA’s strongest boxed warning for embryo-fetal toxicity and will be distributed through a restricted program. That could add extra steps for doctors and patients and make the treatment harder to prescribe and distribute.
Competition is another issue. Multiple myeloma is already crowded with established treatments. Zenbexus will need to show that it offers a clear benefit over existing options if BMY wants it to capture a meaningful share of the market. Investors also need to look at BMY’s broader growth picture. Zenbexus is a welcome addition, but sales will take time to build. The drug may not immediately offset pressure from older products that are seeing weaker sales or approaching loss of exclusivity.
Conclusion
The FDA approval is bullish for Bristol-Myers Squibb Company (NYSE:BMY) because Zenbexus adds another potential growth driver to its oncology portfolio and gives the company a stronger foothold in multiple myeloma. The clinical results, large patient population, and high list price create a meaningful revenue opportunity if the drug gains traction.
Investors should still be cautious. Bristol Myers needs positive confirmatory results, and the drug’s safety requirements and competition could slow its rollout. Overall, the approval improves BMY’s long-term growth outlook, but Zenbexus is more likely to build into a growth driver over time than become an immediate game changer. Its contribution will depend on the confirmatory trial results and how quickly doctors adopt the drug in the multiple myeloma market.
READ NEXT: Starbucks (SBUX)’s Corporate Layoffs Could Strengthen its Turnaround, But Risks Remain and Target (NYSE:TGT) Bets on Grocery to Bring Shoppers Back and Boost Profits
Disclosure: None. This article is originally published at Insider Monkey.
